Search

MannKind Corp

Chiusa

SettoreSettore sanitario

3.51 2.93

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

3.51

Massimo

3.54

Metriche Chiave

By Trading Economics

Entrata

5.7M

13M

Vendite

1.6M

78M

P/E

Media del settore

39.2

34.393

Margine di Profitto

16.793

Dipendenti

403

EBITDA

8.3M

27M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+163.92% upside

Dividendi

By Dow Jones

Utili prossimi

6 nov 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-316M

1.2B

Apertura precedente

0.58

Chiusura precedente

3.51

Notizie sul Sentiment di mercato

By Acuity

14%

86%

21 / 374 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Bullish Evidence

MannKind Corp Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

8 ago 2025, 21:43 UTC

Utili

Constellation Software 2Q Revenue Rises, Profit Shrinks

8 ago 2025, 16:39 UTC

Acquisizioni, Fusioni, Takeovers

Vinci Faces Reduced Earnout Payments to ACS for Cobra IS Deal

8 ago 2025, 22:42 UTC

Acquisizioni, Fusioni, Takeovers

The Paramount Merger Was a Bad Deal for Old Shareholders. Buying the Stock Is a Good Bet for New Ones. -- Barrons.com

8 ago 2025, 21:31 UTC

Discorsi di Mercato
Utili

Cautious Long-Term Outlook For Natural Diamond Prices -- Market Talk

8 ago 2025, 21:00 UTC

Utili

Constellation Software 2Q Rev $2.84B >CSU.T

8 ago 2025, 21:00 UTC

Utili

Constellation Software 2Q Net $56M >CSU.T

8 ago 2025, 21:00 UTC

Utili

Constellation Software 2Q EPS $2.66 >CSU.T

8 ago 2025, 20:55 UTC

Discorsi di Mercato

Ahead of Cisco's Earnings, Investors Should Expect Conservatism -- Market Talk

8 ago 2025, 20:50 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

8 ago 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

8 ago 2025, 20:35 UTC

Discorsi di Mercato

Mexico's Industrial Production Seen Higher in June -- Market Talk

8 ago 2025, 20:28 UTC

Utili

MP Materials Stock Soars Even Higher on Earnings. The Future Looks Bright, Too. -- Barrons.com

8 ago 2025, 20:28 UTC

Utili

These Stocks Moved the Most Today: Trade Desk, Expedia, SoundHound, Pinterest, Gilead, Peloton, and More -- Barrons.com

8 ago 2025, 20:20 UTC

Acquisizioni, Fusioni, Takeovers

Boeing's Spirit AeroSystems Deal Gets U.K. Approval. It's Part of the Turnaround. -- Barrons.com

8 ago 2025, 20:08 UTC

Utili

Tredegar: Recent Decline in Orders, Which Is a Measure of Future Sales Volume, Is Due to Lower Demand for Aluminum Extrusions in U.S. and Customers Pausing Orders to Evaluate New Higher Tariff >TG

8 ago 2025, 19:34 UTC

Discorsi di Mercato

Underwhelming Weight Loss Pill Results Might Not Put Off Consumers -- Market Talk

8 ago 2025, 19:15 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Settle Under $3 -- Market Talk

8 ago 2025, 19:13 UTC

Discorsi di Mercato

Oil Futures End Volatile Week Lower -- Market Talk

8 ago 2025, 18:21 UTC

Discorsi di Mercato

Gold Gains for the Week as Tariffs Go Forward -- Market Talk

8 ago 2025, 17:27 UTC

Utili

These Stocks Are Moving Most Today: Trade Desk, Expedia, SoundHound, Pinterest, Gilead, Microchip, and More -- Barrons.com

8 ago 2025, 17:09 UTC

Utili

Pinterest Stock Gets Multiple Price Target Hikes. Shares Tumble on Earnings Miss. -- Barrons.com

8 ago 2025, 17:03 UTC

Utili

Pinterest Stock Gets Multiple Price Target Hikes. Shares Tumble on Earnings Miss. -- Barrons.com

8 ago 2025, 16:20 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Health Care Roundup: Market Talk

8 ago 2025, 16:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

8 ago 2025, 15:53 UTC

Acquisizioni, Fusioni, Takeovers

Vinci: New Provisions Will Have No Significant Impact on Vinci's Financial Statements

8 ago 2025, 15:51 UTC

Acquisizioni, Fusioni, Takeovers

Vinci, ACS Terminate Agreement Regarding Creation of Joint Venture in Renewable Energy

8 ago 2025, 15:50 UTC

Acquisizioni, Fusioni, Takeovers

Vinci to Pay EUR300M of That Sum to ACS Taking Into Account Payments Already Made

8 ago 2025, 15:48 UTC

Acquisizioni, Fusioni, Takeovers

Vinci, ACS Agreed to Fix Earn-Out Related to Cobra IS Developments in Renewable Energy at EUR380M Payable in Cash

8 ago 2025, 15:47 UTC

Acquisizioni, Fusioni, Takeovers

Vinci: Acquisition of Cobra IS Was Completed Dec. 31, 2021

8 ago 2025, 15:46 UTC

Acquisizioni, Fusioni, Takeovers

Vinci: Agreement Will Definitively Settle Certain Provisions Related to Acquisition of Cobra IS

Confronto tra pari

Modifica del prezzo

MannKind Corp Previsione

Obiettivo di Prezzo

By TipRanks

163.92% in crescita

Previsioni per 12 mesi

Media 9.29 USD  163.92%

Alto 12 USD

Basso 7 USD

Basato su 7 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per MannKind Corp - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

7 ratings

7

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

4.079 / 4.323Supporto e resistenza

A breve termine

Bullish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

Weak Bearish Evidence

Sentiment

By Acuity

21 / 374 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.